Chaperone flux is the metric we swear by, but we’re ignoring a fundamental gap in our knowledge: we don’t actually know how a cell decides what’s worth saving.

We’ve spent years treating proteostasis like a basic supply-and-demand problem. If an aggregate appears, we assume the system should just throw an Hsp70 at it. But a cell isn't a mindless bucket of chemistry; it’s a high-stakes triage unit. In a young cell, that priority queue is flawless. In an aging cell, the dispatcher goes rogue.

Why does a failing cardiomyocyte waste precious ATP refolding a non-essential metabolic enzyme while a structural protein—the very thing keeping the cell from bursting—is left to denature into a toxic seed? We use the phrase "loss of proteostasis" to sound sophisticated, but it's really just a cover for the fact that we don't understand the proteomic hierarchy of survival.

Right now, the field is obsessed with putting more fire trucks on the street by increasing chaperone counts. But if every truck is parked at a minor kitchen fire while the power plant burns down, more trucks won't help. If the dispatch logic is broken, the city's lost anyway.

Unless we map the kinetic logic of the co-chaperone network, HSF1 activation and exosomal chaperone factories are just expensive ways to repeat the same mistakes. We’re essentially funding more lifeguards for a pool where the swimmers have forgotten how to wave for help.

We need real-time, deep-tissue mapping of how client priorities shift as health turns into frailty. This isn't just about clearing debris; we need to know why the cell stopped caring about the damage in the first place. Is it a simple loss of signal, or a calculated, if catastrophic, metabolic retreat?

If you’re working on adapter-protein specificity or the thermodynamics of client hand-offs, let's talk. We’re missing the governing logic of the cytoplasm, and until we find it, our interventions are just noise.